| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,083 | 0,095 | 16:39 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.11. | Mauna Kea Technologies: Pancreatic Cancer Awareness Month: Understanding Cellvizio in Clinical Practice | 450 | Business Wire | Regulatory News:
Dear Shareholders and Investors,
November is Pancreatic Cancer Awareness Month. It highlights a major public health challenge that concerns us all: with the widespread use of... ► Artikel lesen | |
| 09.11. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 350 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 04.11. | Mauna Kea Technologies Announces the Launch of CellTolerance at Cleveland Clinic Abu Dhabi, the First Hospital in the MENA Region to Offer the Program | 451 | Business Wire | Cleveland Clinic Abu Dhabi is ranked #1 for gastroenterology in the Middle East1 A highly promising commercial roll-out that provides access to one of the world's highest-prevalence Irritable... ► Artikel lesen | |
| 20.10. | Mauna Kea Technologies Reports Nine-Month 2026 Sales of €4.4 Million, Up 24% at Constant Exchange Rates | 442 | Business Wire | Nine-month sales of €4.4 million, up 21% as reported and 24% at constant exchange rates (CER) Europe and Rest of World up 128%, led by CellTolerance, now present in 9 countries with 27 paying... ► Artikel lesen | |
| 08.10. | Mauna Kea Technologies Announces 2026 Half-Year Results | 589 | Business Wire | Product and service revenue of €3.2 million, up 37% driven by strong CellTolerance momentum in Europe and new international markets Gross margin on product and service revenue of 65%, up 2 points... ► Artikel lesen | |
| 06.10. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 477 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 07.09. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 476 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 26.08. | Mauna Kea Technologies Announces Publication of a Landmark Systematic Review and Meta-Analysis Reinforcing the Diagnostic Accuracy and Clinical Impact of Cellvizio in Upper Gastrointestinal Cancer | 589 | Business Wire | Largest ever meta-analysis of upper gastrointestinal endomicroscopy pooling 33 studies and 2,350 patients Original research conducted and funded by Korea's National Evidence-Based Healthcare... ► Artikel lesen | |
| MAUNA KEA TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 07.08. | Mauna Kea Technologies: Monthly information regarding the total number of voting rights and shares comprising the share capital | 604 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 28.07. | Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio and Its Combination with AI for the Diagnosis of Pancreatic Cysts | 593 | Business Wire | International interobserver study confirms increase of diagnostic accuracy to 96% for mucinous vs. non-mucinous, and higher physician agreement with Cellvizio AI Cellvizio increases accuracy... ► Artikel lesen | |
| 21.07. | Mauna Kea Technologies Reports Strong H1 2026 Core Sales Growth | 560 | Business Wire | H1 2026 sales reached €3,203K, up +44% at constant exchange rates (CER) and +39% as reported1 CellTolerance sales increased +145% to €0.9 million, driven by strong international expansion Strong... ► Artikel lesen | |
| 16.07. | Mauna Kea Technologies to Host a Webinar on July 21, 2026 To Discuss Its First-Half Business Activity | 492 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, announces... ► Artikel lesen | |
| 16.07. | Mauna Kea Technologies Secures €4 Million Optional Shareholder Loan To Support Commercial Expansion | 2 | pulse2.com | ||
| 15.07. | Mauna Kea Technologies Secures €4.0M Shareholder Loan Agreement to Strengthen Liquidity and Fund Organic Growth | 793 | Business Wire | Shareholder loan agreement with long-term financial partner Vester Finance provides Mauna Kea with the contractual option to draw funds, with no obligation to do so, over the next 24 months Financing... ► Artikel lesen | |
| 06.07. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 407 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 04.06. | Mauna Kea Technologies Announces the Results of its Combined General Meeting of June 4, 2026 | 539 | Business Wire | All resolutions recommended by the Board of Directors were adopted, with the exception of the 15th
Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio,... ► Artikel lesen | |
| 03.06. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 491 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 03.06. | Mauna Kea Technologies Announces New Publication in the UEG Journal Identifying "Triple Healing", a Cellvizio- Assessed Therapeutic Target Associated with Sustained Remission in Ulcerative Colitis | 428 | Business Wire | 100% of patients achieving Cellvizio-assessed triple healing remained relapse-free over 24 months (0 of 29), versus a ~33% relapse rate among those who did not A decade of converging, multi-center... ► Artikel lesen | |
| 20.05. | Mauna Kea Technologies Expands Presence in the Middle East with UAE and Turkey Regulatory Approvals and First CellTolerance Commercial Installation | 573 | Business Wire | IBS-related symptom prevalence in the region is among the highest in the world, reaching an average of 27% An ideal region uniquely positioned for CellTolerance's direct out-of-pocket commercial... ► Artikel lesen | |
| 18.05. | Mauna Kea Technologies Announces Nomination of 3 New Directors | 692 | Business Wire | Their recognized expertise will help accelerate the strategic transformation launched in 2025 Subject to approval at upcoming Annual General Meeting
Regulatory News:
Mauna Kea Technologies... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,062 | -6,10 % | Sernova Biotherapeutics: 11,2 Millionen Dollar für die Fusion - und doch rutscht die Aktie | ||
| FAMICORD | 2,270 | +1,79 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 06.11.2026 | Das Instrument E36 CY0101162119 SED ENERGY HLDGS. DL 0,2 EQUITY wird cum Kapitalmassnahme gehandelt am 06.11.2026 und ex Kapitalmassnahme am 09.11.2026 The instrument E36 CY0101162119 SED ENERGY HLDGS.... ► Artikel lesen | |
| GERATHERM MEDICAL | 2,090 | +1,46 % | Geratherm Medical Aktie: Der Umbau soll die Wende bringen | Geratherm Medical steckt operativ weiter in einer schwierigen Phase. Im ersten Halbjahr 2026 sank der Umsatz um 12,5 Prozent auf 7,0 Millionen Euro, während das EBIT auf minus 0,5 Millionen Euro zurückging.... ► Artikel lesen | |
| CERENOME | 0,585 | +23,55 % | Cerenome outlines $10M-$12.5M 2026 gross billings run rate exit while targeting mid-2027 REYOBIQ top line data | ||
| MEDICLIN | 5,050 | -1,94 % | EQS-News: MEDICLIN AG: Befreiung nach § 37 Abs. 1 und Abs. 2 WpÜG i.V.m. § 9 Satz 1 Nr. 1 WpÜG-AngebVO von den Pflichten nach § 35 Abs. 1 Satz 1, § 35 Abs. 2 Satz 1 WpÜG | EQS-News: MEDICLIN AG
/ Schlagwort(e): Sonstiges
MEDICLIN AG: Befreiung nach § 37 Abs. 1 und Abs. 2 WpÜG i.V.m. § 9 Satz 1 Nr. 1 WpÜG-AngebVO von den Pflichten nach § 35 Abs.... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 1,640 | -1,20 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Nov. 10, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals: Rekord bei Umsatz und Gewinn - lächerliche Bewertung! | Sonoma Pharmaceuticals macht den nächsten gewaltigen Schritt auf dem Weg zum profitablen Wachstumsunternehmen. Nach dem erstmaligen Erreichen eines positiven EBITDA im Vorquartal meldet der Healthcare-Spezialist... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences GAAP EPS of $0.00, revenue of $4.63M | ||
| VERU | 2,180 | -5,22 % | Veru presents data on enobosarm for obesity treatment | ||
| LIFEWARD | 3,260 | +1,88 % | Lifeward GAAP EPS of -$1.32 misses by $0.50, revenue of $5.43M misses by $1.81M | ||
| LIGHT AI | 0,028 | +12,90 % | Light Ai Announces Corporate Restructuring To Support Next Phase Of Quickscan Development | ||
| MAVEN BRANDS | 0,001 | 0,00 % | CSE Bulletin: Delist - Maven Brands Inc. (MJ) | Le 18 novembre/November 2026
The common shares of Maven Brands Inc. will be delisted from the CSE at market close today, November 18, 2026.
Maven Brands Inc. is currently suspended. See Bulletin... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 37,860 | -1,82 % | EQS-News: Fresenius SE & Co. KGaA: Fresenius schließt Verkauf von 13,4 Millionen Aktien der Fresenius Medical Care zu 39,00 Euro je Aktie ab und erzielt rund 524 Millionen Euro | EQS-News: Fresenius SE & Co. KGaA
/ Schlagwort(e): Beteiligung/Unternehmensbeteiligung
Fresenius schließt Verkauf von 13,4 Millionen Aktien der Fresenius Medical Care zu 39,00... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 43,860 | +0,05 % | Aktie zieht an!: Siemens liefert und legt nach, die Strategie überzeugt wirft Fragen auf | © Foto: Joko - JokoSiemens meldet Rekordzahlen und hebt die Mittelfristziele an. Anleger bleiben trotzdem skeptisch, denn die neue Konzernstrategie gilt vielen noch als zu unscharf Enthaltene Werte:... ► Artikel lesen | |
| FRESENIUS | 52,38 | -1,97 % | EQS-News: Fresenius SE & Co. KGaA: Moody's hebt Kreditausblick für Fresenius von stabil auf positiv an | EQS-News: Fresenius SE & Co. KGaA
/ Schlagwort(e): Rating
Moody's hebt Kreditausblick für Fresenius von stabil auf positiv an (News mit Zusatzmaterial)
19.11.2026 / 13:45... ► Artikel lesen |